Strs Ohio Fate Therapeutics Inc Transaction History

Strs Ohio

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 25, 2022	SELL	$17.78 - $42.39 $142,240 - $339,120	-8,000 Reduced 94.12%	500 $12,000
Q1 2022 Apr 21, 2022	SELL	$29.67 - $60.28 $118,680 - $241,120	-4,000 Reduced 32.0%	8,500 $329,000
Q4 2021 Jan 24, 2022	SELL	$47.84 - $64.34 $253,552 - $341,002	-5,300 Reduced 29.78%	12,500 $731,000
Q2 2021 Jul 26, 2021	BUY	$67.25 - $92.52 $134,500 - $185,040	2,000 Added 12.66%	17,800 $1.54 Million
Q1 2021 Apr 23, 2021	BUY	$72.16 - $117.4 $346,368 - $563,520	4,800 Added 43.64%	15,800 $1.3 Million
Q4 2020 Jan 25, 2021	BUY	$38.09 - $100.95 $220,922 - $585,510	5,800 Added 111.54%	11,000 $1 Million
Q3 2020 Dec 14, 2020	BUY	$30.41 - $40.5 $76,025 - $101,250	2,500 Added 92.59%	5,200 $207,000
Q2 2020 Jul 23, 2020	BUY	$20.21 - $35.23 $54,567 - $95,120	2,700 New	2,700 $92,000
Q1 2020 Apr 23, 2020	SELL	$17.28 - $31.88 $1.38 Million - $2.55 Million	-80,000 Closed	0 $0
Q4 2018 Jan 23, 2019	SELL	$11.48 - $16.98 $13,776 - $20,376	-1,200 Reduced 1.48%	80,000 $1.03 Million
Q2 2018 Aug 06, 2018	BUY	$9.16 - $13.48 $642,116 - $944,948	70,100 Added 631.53%	81,200 $920,000
Q3 2017 Oct 23, 2017	BUY	$2.6 - $4.31 $28,860 - $47,840	11,100	11,100 $43,000

176

113M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $123M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

Stay updated on Strs Ohio with notifications on news.